EPİTELİYAL OVER KANSERİNDE UZUN DÖNEM SAĞ KALIMLA İLİŞKİLİ KLİNİK VE EPIDEMİYOLOJİK ÖZELLİKLER

Year 2021, Volume: 18 Issue: 3, 901 - 906, 25.09.2021

Koray Aslan , Zeliha Fırat Cüylan , Şükran Kozalı Murat Öz

https://doi.org/10.38136/jgon.907258

Abstract

Amaç: Epitelyal over kanseri (EOK) hastalarında uzun dönem sağ kalımla ilişkili klinik ve epidemiyolojik risk faktörlerini tanımlamak.
Gereçler ve Yöntem: Jinekolojk onkoloji kliniğimizde Aralık, 2006 ve Ocak, 2019 tarihleri arasında epitelyal over kanseri tansı alan tüm hastaların tıbbi kayıtları incelenmiştir. Çalışmaya EOK tanısı ile evreleme cerrahisi yapılan ve adjuvant platin bazlı kemoterapi alan hastalar dahil edilmiştir. Tıbbi kayıtları eksik, platin dirençli veya Aralık, 2020 tarihi itibatri ile hayatta olup takip süresi 84 aydan kısa olan olgular çalışma dışında bırakılmıştır. Uzun dönem sağ kalım tanı aldıktan sonra ≥7 yıl yaşayan hastaları tanımlamak için kullanılmıştır. Hastalar sağ kalım ≥7 yıl ve sağ kalım <7 yıl olarak gruplandırılmıştır. Gruplar, klinik ve epidemiyolojik faktörler açısından Mann Whitney U ve ki-kare testleri kullanılarak karşılaştırılmıştır.
Bulgular: Her iki grup arasında yaş (p=0,33), menapoz durumu (p=0,78), dahili hastalık (p=0,11), ailede malignite öyküsü (p=0,80), Eastern Cooperative Oncology Group performans skoru (p=1,0), CA 125 düzeyi (p=0,66), optimal sitoredüksiyon (p=0,72), neoadjuvant kemoterapi (p=1,0) ve International Federation of Gynecology and Obstetrics (FIGO) evresi (p=0,42) açısından anlamlı fark saptanmadı.
Sonuç: Çalışmamızda sitoredüktif cerrahi uygulanan platin sensitif EOK’li kadınlarda uzun dönem sağ kalım ile ilişkili herhangi bir klinik veya epidemiyolojik faktör saptanamamıştır.

Keywords

Over kanseri, Prognostik faktörler, Uzun dönem sağ kalım

Supporting Institution

yok

Project Number

yok

CLINICAL AND EPIDEMIOLOGICAL CHARACTERISTICS ASSOCIATED WITH LONG-TERM SURVIVAL IN EPITHELIAL OVARİAN CANCER

Abstract

Aim: To identify clinical and epidemiological risk factors associated with long-term survival in epithelial ovarian cancer (EOC) patients.
Materials and Method: Medical records of all patients who received an epithelial ovarian cancer diagnosis between December 2006 and January 2019 in our gynecological oncology clinic were examined. Patients who underwent staging surgery with a diagnosis of EOC and received adjuvant platinum-based chemotherapy were included in the study. Patients with incomplete medical records, platinum-resistant or alive as of December 2020, and having a follow-up period of fewer than 84 months were excluded from the study. Long-term survival has been used to describe patients living ≥7 years after diagnosis. Patients were grouped as survival ≥7 years and survival <7 years. The Groups were compared in terms of clinical and epidemiological factors by using Mann-Whitney U and chi-square tests.
Results: The two groups were comparable with regard to age (p=0.33), menapausal state (p=0.78), chronic disease (p=0.11), positive family history for malignancy (p=0.80), Eastern Cooperative Oncology Group performans skoru (p=1.0), CA 125 levels (p=0.66), optimal cytoreduction (p=0.72), neoadjuvant chemotherapy (p=1.0), International Federation of Gynecology and Obstetrics (FIGO) stage (p=0.42).
Conclusion: According to the results of our study, we found no clinical or epidemiological factors associated with long-term survival in women with platinum-sensitive EOC who underwent cytoreductive surgery.

Keywords

Long-term survival, Ovarian cancer, Prognostic factors

Project Number

yok

References

• [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68:7
• [2] Sørensen SM, Bjørn SF, Jochumsen KM, Jensen PT, Thranov IR, Hare-Bruun H, et al. Danish gynecological cancer database. Clin Epidemiol 2016;8:485–90.
• [3] Cress RD, Chen YS, Morris CR, Petersen M, Leiserowitz GS. Characteristics of long-term survivors of epithelial ovarian cancer. Obstet Gynecol 2015;126:491–7.
• [4] Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2007;25:3621–7.
• [5] Saner FAM, Herschtal A, Nelson BH, deFazio A, Goode EL, Ramus SJ, et al. Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nat Rev Cancer 2019;19:339–48.
• [6] Engel J, Eckel R, Schubert-Fritschle G, Kerr J, Kuhn W, Diebold J, et al. Moderate progress for ovarian cancer in the last 20 years: Prolongation of survival, but no improvement in the cure rate. Eur J Cancer 2002;38:2435–45.
• [7] Horowitz NS, Miller A, Rungruang B, Richard SD, Rodriguez N, Bookman MA, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: An analysis of GOG 182. J Clin Oncol 2015;33:937–43.
• [8] Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 2005;11:3686–96.
• [9] Åkeson M, Jakobsen AM, Zetterqvist BM, Holmberg E, Brännström M, Horvath G. A population-based 5-year cohort study including all cases of epithelial ovarian cancer in western sweden: 10-year survival and prognostic factors. Int J Gynecol Cancer 2009;19:116–23.
• [10] Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol 2018;148:204–12.
• [11] Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, et al. Adjuvant Therapy in Stage I and Stage II Epithelial Ovarian Cancer. N Engl J Med 1990;322:1021–7.
• [12] Chan JK, Tian C, Monk BJ, Herzog T, Kapp DS, Bell J, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: A Gynecologic Oncology Group study. Cancer 2008;112:2202–10.
• [13] Clarke CL, Kushi LH, Chubak J, Pawloski PA, Bulkley JE, Epstein MM, et al. Predictors of long-term survival among high-grade serous ovarian cancer patients. Cancer Epidemiol Biomarkers Prev 2019;28:996–9.
• [14] Dao F, Schlappe BA, Tseng J, Lester J, Nick AM, Lutgendorf SK, et al. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma. Gynecol Oncol 2016;141:260–3.
• [15] Hamilton CA, Miller A, Casablanca Y, Horowitz NS, Rungruang B, Krivak TC, et al. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol 2018;148:275–80.
• [16] Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 2012;120:612–8.
• [17] Javellana M, Hoppenot C, Lengyel E. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecol Oncol 2019;152:228–34.
• [18] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29.
• [19] Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 2004;22:4648–58.
• [20] Nikas JB, Boylan KLM, Skubitz APN, Low WC. Mathematical prognostic biomarker models for treatment response and survival in epithelial ovarian cancer. Cancer Inform 2011;10:233–47.